Pyrexia Clinical Trial
Official title:
Combined Spinal and Epidural Anesthesia and Maternal Intrapartum Temperature During Vaginal Delivery: a Randomized Clinical Trial
Maternal intra-partum fever commonly complicates the process of labour. Its occurrence is often regarded as being synonymous with the presence of chorioamnionitis. This inevitably results in the administration of antibiotics to the affected mother. Review of the literature however suggests that this approach is not always appropriate. Non-infective causes of this condition that are often overlooked include the use of epidural analgesia for pain relief, normal thermal physiological changes in women not using any form of analgesia and delivery in an overheated room. Women with certain risk factors such as nulliparity and a long latent phase of labour are also more prone to developing maternal intra-partum fever. Irrespective of its aetiology, maternal intra-partum fever carries risks both for the mother and her unborn child. Putting more thought into the care of these patients will go a long way in reducing the maternal and neonatal morbidity associated with this complication.The combined spinal-epidural (CSE) technique has been introduced in an attempt to reduce these adverse effects. CSE is believed to during labour provide more rapid onset of analgesia than epidural analgesia, The incidence of fever is significantly lower with CSE technique.
The objective this study is determine the fever maternal incidence with CSE technique for
labor analgesia.
METHODS: a randomized open clinical trial will be conducted involving Seventy healthy, term,
nulliparous women in spontaneous labor were assigned to either CSE technique or non
pharmacologic analgesia for labor.these patients will be randomly assigned to receive or not
CSE technique for labor analgesia. Outcomes analysis wiil include maternal fever, pain
intensity measured by visual analog scale, labor duration, c-section and instrumental
delivery. statical analysis will performed using Mann-Whitney and Fisher" exact test 5%
level of significance.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04397380 -
COVID-19 Thales Thermography Triage : Thermal Camera Feasibility Study
|
||
Completed |
NCT00438269 -
Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection
|
Phase 2 | |
Recruiting |
NCT04652258 -
Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated With Dabrafenib/ Trametinib +/- Immunotherapy
|
Phase 2 |